About Aquinox Pharma
Aquinox Pharma is a Healthcare company based in Vancouver (Canada) founded in 2004, and was acquired by Taro in July 2020. Small molecule targeting PI3K pathway. Aquinox Pharma has raised $70.59 million across 6 funding rounds from investors including Pfizer, Taro Pharmaceutical Industries and Ventures West. Aquinox Pharma has completed 1 acquisition, including Neoleukin Therapeutics. Its focus areas include Life Sciences, Oncology, Drugs and Blood Cancer.
Company details
Aquinox Pharmaceuticals was established in 2004 in Vancouver, Canada, within the pharmaceutical sector. Therapeutics are developed for inflammation and immuno-oncology, with emphasis on candidates that target SHIP1, a regulator of the PI3K signaling pathway in immune cells. The lead candidate, AQX-1125, functions as a small molecule activator for oral administration. Clinical trials have been completed for AQX-1125, and Phase 3 development is underway for bladder pain syndromeinterstitial cystitis.
- Headquarters Vancouver, Canada
- Stage Acquired
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Website aqxpharma.com
- Social LinkedIn X Facebook
- Acquired by Taro (Jul 2020)
Funding Insights of Aquinox Pharma
Aquinox Pharma has successfully raised a total of $70.59M across 6 strategic funding rounds. The most recent funding activity was a Series C round of $18 million completed in April 2013. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $70.59M
- Total Rounds 6
- Last Round Series C — $18M
- First Round $14.5M
(Jun 2007)
- Investors Count 8
All 6 funding rounds of Aquinox Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2013 | $18M | Series C | – | Johnson & Johnson Innovation | |
| Sep 2011 | $3.54M | Series B | – | – | – |
| Jan 2011 | $4.72M | Series B | – | – | – |
| Jun 2010 | $25M | Series B | – | Pfizer | |
| Apr 2010 | $4.83M | Series A | – | – | – |
| Jun 2007 | $14.5M | Series A | – | – |
9 investors in total: 9 institutional.
Investors in Aquinox Pharma
Aquinox Pharma has secured backing from 9 investors, including institutional and venture fund investors. Prominent investors backing the company include Pfizer, Taro Pharmaceutical Industries and Ventures West.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early-stage investments in Canadian companies are made by Ventures West. | ventureswest.com | Vancouver, Canada | ||
| augment-investments.com | ||||
Early-stage life sciences investments are made globally by Inbio Ventures. | inbio-ventures.com | Moscow, Russia | ||
Venture capital firm backed by Johnson & Johnson | jnjinnovation.com/jjdc | Cambridge, United States | ||
Gold IRA custodian services are provided by BC Advantage Funds. | 2015 | bcadvantagefunds.com | ||
Private equity firm focused on consumer brands | lioncapital.com | London, United Kingdom | ||
Pharmaceutical products for treating multiple diseases are provided. | 1849 | pfizer.com | New York, United States | |
| jnjinnovation.com | ||||
Taro Pharmaceutical Industries is engaged in developing and distributing pharmaceuticals. | 1950 | taro.com | Haifa, Israel |
Investor details for Aquinox Pharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Aquinox Pharma
10 people are tracked at Aquinox Pharma (1 in leadership, 8 in board & advisors, 1 in team).
| Name | Role | Group |
|---|---|---|
Priti Patel | Chief Medical Officer | Leadership |
Todd Simpson | Board Member | Board & advisors |
Sarah Noonberg | Board Member | Board & advisors |
Cantey Boyd | Board Member | Board & advisors |
Daniel-Adriano Silva | Scientific Advisor | Board & advisors |
Erin Lavelle | Board Member | Board & advisors |
Martin Babler | Board Member | Board & advisors |
Rohan Palekar | Board Member | Board & advisors |
Kamran Alam | Senior Strategic Advisor | Board & advisors |
James Chesko | Formulation Scientist | Team |
Complete people profiles for Aquinox Pharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Aquinox Pharma
Aquinox Pharma has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Neoleukin Therapeutics.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Therapeutic proteins are developed for immunological disorders using computational methods. | neoleukin.com | Seattle, United States | 2003 | Aug 2019 | •••• |
Complete acquisition details for Aquinox Pharma
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Aquinox Pharma
6 dated milestones of Aquinox Pharma across 16 years, from founding to its latest funding, stage changes and deals.
- Founded Aquinox Pharma is founded.
- Funding First funding round of $14.5M.
- Funding Latest funding round, Series C, of $18.0M.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Neoleukin Therapeutics.
- Exit Acquired by Taro.
Web traffic of Aquinox Pharma
The website of Aquinox Pharma (aqxpharma.com) receives about 3K visits a month and ranks #6,768,702 among all websites worldwide, #6,761 in Biotechnology and Pharmaceuticals.
- Monthly visits3K
▲ 3.1% vs previous month
- Unique visitors1.3K
per month
- Global rank#6,768,702
among all websites
- Category rank#6,761
Health · Biotechnology and Pharmaceuticals
- Bounce rate38%
- Pages per visit1.1
- DevicesDesktop 23% · Mobile 77%
Websites whose visitors overlap most with Aquinox Pharma. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| achaogen.com | 100% | View details | |||
| phasebio.com | 94% | 2.2K | #11,529,454 | View details | |
| afnm.com | 93% | View details | |||
| thresholdpharm.com | 93% | View details | |||
| pherin.com | 93% | View details | |||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 9 similar websites and full traffic analytics for Aquinox Pharma
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 9 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Aquinox Pharma
Aquinox Pharma was founded in 2004 and raised its 1st funding round 3 years after it was founded.
Aquinox Pharma is headquartered in Vancouver, Canada. It is registered at Vancouver, British Columbia, Canada.
Aquinox Pharma is a funded company, having raised a total of $70.59M across 6 funding rounds to date. The company's 1st funding round was a Series A of $14.5M, raised on Jun 2007.
Aquinox Pharmaceuticals was established in 2004 in Vancouver, Canada, within the pharmaceutical sector. Therapeutics are developed for inflammation and immuno-oncology, with emphasis on candidates that target SHIP1, a regulator of the PI3K signaling pathway in immune cells. The lead candidate, AQX-1125, functions as a small molecule activator for oral administration. Clinical trials have been completed for AQX-1125, and Phase 3 development is underway for bladder pain syndromeinterstitial cystitis.
Aquinox Pharma has made 1 acquisition, including Neoleukin Therapeutics.
Aquinox Pharma has 9 investors. Key investors include Pfizer, Taro Pharmaceutical Industries, Ventures West, Augment Investments, and Johnson & Johnson Innovation.
Yes. Aquinox Pharma was acquired by Taro in July 2020.